Study of WAL0921 in Patients With Glomerular Kidney Diseases
Recruiting
Phase 2
Interventional Study
Diabetic Nephropathies
Primary Focal Segmental Glomerulosclerosis
Minimal Change Disease
Primary Immunoglobulin A Nephropathy
Primary Membranous Nephropathy
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 96 (estimated)
- Sponsor
- Walden Biosciences · Industry
Who this trial is looking for
This trial is looking for adults between 18 and 75 years old who have certain types of kidney diseases. They cannot be pregnant, have a history of organ transplants, or have had serious kidney problems in the past six months. If you have issues with alcohol or drugs, that would also prevent you from joining.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change di…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults, age 18-75 years
* Diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis; treatment resistant-minimal change disease; primary IgA nephropathy; primary membranous nephropathy
* eGFR greater than or …
Contacts